Healthcare / BiotechnologyNasdaqGS
$1.54
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-110.1M · quality 53.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$111M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-209.1%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-61.8M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-61.8M | $-61.8M | $-138.4M | $-117.3M | $-81.8M | $-41.6M | $-5.3M | $-1.2M |
| EPS | -1.18 | -1.18 | -3.83 | -3.44 | -2.80 | -1.74 | -0.51 | — |
| Cash Flow | ||||||||
| Free Cash Flow | — | — | $-120.3M | $-100.0M | $-63.4M | $-38.6M | $-4.5M | — |
| Returns | ||||||||
| ROE | -209.1% | -209.1% | -268.4% | -69.3% | -75.4% | -23.2% | -103.0% | 5704.8% |
| Growth & Yield | ||||||||
| EPS Growth | 69.2% | 69.2% | -11.3% | -22.9% | -60.9% | -241.2% | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.